(Q37132845)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

main subject

chronic myeloid leukemia

0 references

leukemia

1 reference

based on heuristic

inferred from title

neoplastic stem cells

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Michael Deininger

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

604-609

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

Molecular mechanisms of transformation by the BCR-ABL oncogene

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Chronic myeloid leukaemia as a model of disease evolution in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

The biology of normal and neoplastic stem cells in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801923212

10.1080/10428190801923212

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18398718%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference